Posted by Michael Wonder on 28 Feb 2017
OncoSec granted FDA fast track designation for ImmunoPulse IL-12 for the treatment of metastatic melanoma following progression on pembrolizumab or nivolumab
28 February 2017 - Provides opportunities for upcoming Phase 2b PISCES clinical trial and future clinical development.
OncoSec received Fast Track designation from the U.S. FDA for its ImmunoPulse IL-12, a potentially first-in-class, Intratumoral anti-cancer gene therapy that expresses interleukin-12 (IL-12) for the treatment of metastatic melanoma, following progression on pembrolizumab or nivolumab.
